Human cellular immune responses against human papillomaviruses in cervical neoplasia

Expert Reviews in Molecular Medicine

Volumn 1, Issue 5, 1998, Pages 1-19

  Man, Stephen ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

CaCx; cervical cancer; cervical intraepithelial neoplasia; cervical neoplasia; CIN; CTL; cytokine; HPV; HPV16; HPV18; human papillomavirus; immune response; T cells

Indexed keywords

EID: 0003236466     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399498000210     Document Type: Article

References (69)

1. Boyle, P. (1997) Global burden of cancer. Lancet 349 (suppl. II), 23–26
2. Cannistra, S.A. and Niloff, J.M. (1996) Cancer of the uterine cervix. N. Engl. J. Med. 334, 1030–1038
3. Forsmo, S. et al. (1997) Treatment of pre-invasive conditions during opportunistic screening and its effectiveness on cervical cancer incidence in one Norwegian country. Int. J. Cancer 71, 4–8
4. Soutter, W.P. et al. (1997) Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia [see comments]. Lancet 349, 978–980
5. Stockton, D., Cooper, P. and Lonsdale, R. (1997) Changing incidence of invasive adenocarcinoma of the uterine cervix in East Anglia. J. Med. Screen. 4, 40–43
6. Frazer, I.H. (1996) Immunology of papillomavirus infection. Curr. Opin. Immunol. 8, 484–491
7. Suzich, J.A. et al. (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA 92, 11553–11557
8. Ho, G.Y.F. et al. (1998) Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338, 423–428
9. Halpert, R. et al. (1986) Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet. Gynecol. 68, 251–258
10. Petry, K.U. et al. (1994) Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int. J. Cancer 57, 836–840
11. Coleman, N. et al. (1994) Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102, 768–774
12. Jarrett, W.F. et al. (1991) Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 184, 33–42
13. Knowles, G., O'Neil, B.W. and Campo, M.S. (1996) Phenotypical characterization of lymphocytes infiltrating regressing papillomas. J. Virol. 70, 8451–8458
14. Selvakumar, R. et al. (1997) Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression. J. Virol. 71, 5540–5548
15. Tosi, P. et al. (1992) Prognostic factors in invasive cervical carcinomas associated with human papillomavirus (HPV). Path. Res. Pract. 188, 866–873
16. zur Hausen, H. and de Villiers, E.M. (1994) Human papillomaviruses. Annu. Rev. Microbiol. 48, 427–447
17. Crook, T. et al. (1989) Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. 8, 513–519
18. Vousden, K.H. (1994) Interactions between papillomavirus proteins and tumor suppressor gene products. Adv. Cancer Res. 64, 1–24
19. Bal, V. et al. (1990) Antigen presentation by keratinocytes induces tolerance in human T cells. Eur. J. Immunol. 20, 1893–1897
20. Ramensee, H. (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7, 85–96
21. Glew, S.S. et al. (1992) HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res. 52, 4009–4016
22. Ferguson, A. et al. (1985) Expression of MHC products and leucocyte differentiation antigens in gynaecological neoplasms: an immunohistological analysis of the tumour cells and infiltrating leucocytes. Br. J. Cancer 52, 551–563
23. Coleman, N. and Stanley, M.A. (1994) Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int. J. Cancer 56, 314–319
24. Tay, S.K. et al. (1987) Subpopulations of Langerhans cells in cervical neoplasia. Br. J. Obstet. Gynaecol. 94, 10–15
25. Jaraquemada, D., Marti, M. and Long, E.O. (1990) An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J. Exp. Med. 172, 947–954
26. Nuchtern, J.G., Biddison, W.E. and Klausner, R.D. (1990) Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 343, 74–76
27. Carbone, F.R. and Bevan, M.J. (1990) Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J. Exp. Med. 171, 377–387
28. Speidel, K. et al. (1997) Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur. J. Immunol. 27, 2391–2399
29. Lee, A.K. and Eisinger, M. (1976) Cell-mediated immunity (CMI) to human wart virus and wart-associated tissue antigens. Clin. Exp. Immunol. 26, 419–424
30. Cubie, H.A. et al. (1989) Lymphoproliferative response to fusion proteins of human papillomaviruses in patients with cervical intraepithelial neoplasia. Epidemiol. Infect. 103, 625–632
31. Altmann, A. et al. (1992) Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7. Eur. J. Cancer 28, 326–333
32. Strang, G. et al. (1990) Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction and virus type specificity. J. Gen. Virol. 71, 423–431
33. Luxton, J.C. et al. (1996) Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J. Gen. Virol. 77, 1585–1593
34. Shepherd, P.S. et al. (1996) Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia. J. Gen. Virol. 77, 593–602
35. Luxton, J.C. et al. (1997) Serological and T helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls. J. Gen. Virol. 78, 917–923
36. Kadish, A.S. et al. (1994) Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific. J. Gen. Virol. 75, 2277–2284
37. Kadish, A.S. et al. (1997) Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J. Natl. Cancer Inst. 89, 1285–1293
38. de Gruijl, T.D. et al. (1996) T-cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J. Gen. Virol. 77, 2183–2191
39. Clerici, M. et al. (1997) Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J. Natl. Cancer Inst. 89, 245–250
40. de Gruijl, T.D. (1998) Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res. 58, 1700–1706
41. Stern, P.L. (1996) Immunity to human papillomavirus-associated cervical neoplasia. Adv. Cancer Res. 69, 175–211
42. Meneguzzi, G. et al. (1991) Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181, 62–69
43. Chen, L.P. et al. (1991) Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA 88, 110–114
44. Chen, L. et al. (1992) Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J. Immunol. 148, 2617–2621
45. Beverley, P.C. et al. (1994) Strategies for studying mouse and human immune responses to human papillomavirus type 16. In Ciba Found. Symp. 187, pp. 78–86, Wiley, Chichester, UK
46. Tindle, R.W. and Frazer, I.H. (1994) Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr. Top. Microbiol. Immunol. 186, 217–253
47. Melief, C.J.M. et al. (1996) Peptide based cancer vaccines. Curr. Opin. Immunol. 8, 651–657
48. Tindle, R.W. (1996) Human papillomavirus vaccines for cervical cancer. Curr. Opin. Immunol. 8, 643–650
49. Borysiewicz, L.K. et al. (1996) A recombinant vaccinia virus encoding human papillomavirus type 16 and type 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347, 1523–1527
50. Ressing, M.E. et al. (1996) Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A∗0201-restricted E7-encoded epitope. Cancer Res. 56, 582–588
51. Evans, E.M. et al. (1997) Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res. 57, 2943–2950
52. Jochmus, I. et al. (1997) Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7 derived peptide. J. Gen. Virol. 78, 1689–1695
53. Evans, C. et al. (1996) HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol. Immunother. 42, 151–160
54. Nakagawa, M. et al. (1997) Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J. Infect. Dis. 175, 927–931
55. Nimako, M. et al. (1997) Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res. 57, 4855–4861
56. Ostor, A.G. (1993) Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12, 186–192
57. McMichael, A. and O'Callaghan, C. (1998) A new look at T cells. J. Exp. Med. 187, 1367–1371
58. Bontkes, H.J. et al. (1997) Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br. J. Cancer 76, 1353–1360
59. Connor, M.E. and Stern, P.L. (1990) Loss of MHC class-I expression in cervical carcinomas. Int. J. Cancer 46, 1029–1034
60. Cromme, F.V. et al. (1994) Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179, 335–340
61. Ikeda, H. et al. (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6, 199–208
62. Bontkes, H. et al. (1998) Specific HLA class I downregulation is an early event in cervical dysplasia associated with clinical progression. Lancet 351, 187–188
63. Ellis, J.R. et al. (1995) The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat. Med. 1, 464–470
64. Smith, G. (1996) Virus proteins that bind cytokines, chemokines or interferons. Curr. Opin. Immunol. 8, 467–471
65. Riddell, S.R. et al. (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238–241
66. Papadopoulos, E.B. et al. (1994) Infusions of donor leukocytes to treat Epstein Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185–1191
67. Rooney, C.M. et al. (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein- Barr-virus-related lymphoproliferation. Lancet 345, 9–13
68. Ressing, M.E. et al. (1995) Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A∗0201 binding peptides. J. Immunol. 154, 5934–5943
69. Konya, J. et al. (1997) Identification of a cytotoxic T lymphocyte epitope in the human papillomavirus type 16 E2 protein. J. Gen. Virol. 78, 2615–2620